首页 > 最新文献

Drug, Healthcare and Patient Safety最新文献

英文 中文
Long-Term Safety and Effectiveness of Calcium Channel Blockers in Hypertension: A Systematic Review. 钙通道阻滞剂治疗高血压的长期安全性和有效性:一项系统综述。
IF 3.4 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2026-03-18 eCollection Date: 2026-01-01 DOI: 10.2147/DHPS.S576249
Nur Aisyah, Jihan Sadira Aurellia, Widya Norma Insani

Purpose: Calcium channel blockers (CCBs) are widely used as first-line therapy for hypertension, but concerns remain regarding their long-term safety and effectiveness. This review aims to systematically summarize the existing evidence on the long-term safety and effectiveness of CCBs in patients with hypertension.

Methods: A systematic review was conducted using the PubMed database to identify randomized controlled trials (RCTs), cohort studies, and case-control studies assessing the long-term use (≥1 year) of CCBs in adult hypertensive populations. Eligible studies compared CCBs with other antihypertensive agents or placebo and reported outcomes related to systemic safety and effectiveness. The quality of each study was assessed using the Jadad and Newcastle-Ottawa Scales. Evidence was synthesized descriptively and stratified by organ system and clinical outcome.

Results: In total, 29 studies met the inclusion criteria, encompassing both RCTs and observational studies. Long-term CCB use was generally safe, with manageable risks. Renal protective effects were less consistent, while several studies reported a marginal increase in the incidence of new-onset diabetes. Associations with breast cancer remained inconclusive, and the risk of bone fractures appeared modestly reduced. Other systemic effects, including metabolic and reproductive changes, were generally mild. In terms of effectiveness, CCBs consistently reduced stroke incidence, although evidence regarding other cardiovascular outcomes, such as infarction, heart failure, and transient ischemic events, was inconsistent across studies.

Conclusion: Overall, CCBs are safe for long-term use and show sustained effectiveness in stroke and angina, although evidence for heart failure, myocardial infarction, and transient ischemic attack remains inconsistent.

目的:钙通道阻滞剂(CCBs)被广泛用作高血压的一线治疗药物,但其长期安全性和有效性仍值得关注。本综述旨在系统总结现有证据,证明CCBs对高血压患者的长期安全性和有效性。方法:使用PubMed数据库进行系统评价,以确定评估成年高血压人群长期(≥1年)使用CCBs的随机对照试验(rct)、队列研究和病例对照研究。符合条件的研究将CCBs与其他抗高血压药物或安慰剂进行了比较,并报告了与全身安全性和有效性相关的结果。使用Jadad和Newcastle-Ottawa量表评估每项研究的质量。根据器官系统和临床结果对证据进行描述性综合和分层。结果:总共有29项研究符合纳入标准,包括随机对照试验和观察性研究。长期使用建行总体上是安全的,风险可控。肾脏保护作用不太一致,而一些研究报告了新发糖尿病发病率的边际增加。与乳腺癌的关联仍不确定,骨折的风险似乎略有降低。其他系统影响,包括代谢和生殖变化,通常是轻微的。在有效性方面,CCBs持续降低卒中发生率,尽管关于其他心血管结局的证据,如梗死、心力衰竭和短暂性脑缺血事件,在研究中不一致。结论:总体而言,CCBs长期使用是安全的,并且在中风和心绞痛中显示出持续的有效性,尽管心力衰竭、心肌梗死和短暂性脑缺血发作的证据仍不一致。
{"title":"Long-Term Safety and Effectiveness of Calcium Channel Blockers in Hypertension: A Systematic Review.","authors":"Nur Aisyah, Jihan Sadira Aurellia, Widya Norma Insani","doi":"10.2147/DHPS.S576249","DOIUrl":"https://doi.org/10.2147/DHPS.S576249","url":null,"abstract":"<p><strong>Purpose: </strong>Calcium channel blockers (CCBs) are widely used as first-line therapy for hypertension, but concerns remain regarding their long-term safety and effectiveness. This review aims to systematically summarize the existing evidence on the long-term safety and effectiveness of CCBs in patients with hypertension.</p><p><strong>Methods: </strong>A systematic review was conducted using the PubMed database to identify randomized controlled trials (RCTs), cohort studies, and case-control studies assessing the long-term use (≥1 year) of CCBs in adult hypertensive populations. Eligible studies compared CCBs with other antihypertensive agents or placebo and reported outcomes related to systemic safety and effectiveness. The quality of each study was assessed using the Jadad and Newcastle-Ottawa Scales. Evidence was synthesized descriptively and stratified by organ system and clinical outcome.</p><p><strong>Results: </strong>In total, 29 studies met the inclusion criteria, encompassing both RCTs and observational studies. Long-term CCB use was generally safe, with manageable risks. Renal protective effects were less consistent, while several studies reported a marginal increase in the incidence of new-onset diabetes. Associations with breast cancer remained inconclusive, and the risk of bone fractures appeared modestly reduced. Other systemic effects, including metabolic and reproductive changes, were generally mild. In terms of effectiveness, CCBs consistently reduced stroke incidence, although evidence regarding other cardiovascular outcomes, such as infarction, heart failure, and transient ischemic events, was inconsistent across studies.</p><p><strong>Conclusion: </strong>Overall, CCBs are safe for long-term use and show sustained effectiveness in stroke and angina, although evidence for heart failure, myocardial infarction, and transient ischemic attack remains inconsistent.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":"18 ","pages":"576249"},"PeriodicalIF":3.4,"publicationDate":"2026-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13005972/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147503021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Rapid Mapping Review of Medication Burden in Adults with an Intellectual Disability: What We Know and What We Do Not Know. 成人智障患者药物负担的快速图谱回顾:我们知道的和我们不知道的。
IF 3.4 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2026-03-11 eCollection Date: 2026-01-01 DOI: 10.2147/DHPS.S558001
Sandra Marquis, Renée O'Leary, N Esmé Marquis, Jennifer Baumbusch

This study asked the questions: what is known and what is not known about medication burden in adults with an intellectual disability. We used a rapid mapping review methodology to collate, describe and catalog the wide variety of evidence in this area. Ninety-one studies were included. Study characteristics, indicators of medication burden and sub-populations at increased risk were catalogued in a table and tabulated as tree maps. The authors concluded that there is evidence of a high medication burden in this population, and that the burden is highest in older adults with an ID, those living in supervised housing and those with diagnosed comorbidities and multi-morbidities. Areas that need further exploration are the total burden of medications used, including the age at which medications are first prescribed and the duration of medication use; the long-term effects of a high medication burden; and the long-term effects of anticholinergic burden. In addition, there is little information on the effects of demographic factors such as race and income.

这项研究提出了这样的问题:关于智力残疾成人的药物负担,我们知道什么,不知道什么。我们使用快速制图审查方法来整理、描述和编目这一领域的各种证据。纳入了91项研究。研究特征、药物负担指标和风险增加的亚人群被编目成表格,并以树状图的形式制成表格。作者得出结论,有证据表明,这一人群的药物负担很高,而且在有身份证的老年人、住在有监督的住房中的老年人、诊断出患有合并症和多种疾病的老年人中,药物负担最高。需要进一步探索的领域是使用药物的总负担,包括首次开处方的年龄和使用药物的持续时间;高药物负担的长期影响;以及抗胆碱能负荷的长期影响。此外,关于种族和收入等人口因素影响的信息也很少。
{"title":"A Rapid Mapping Review of Medication Burden in Adults with an Intellectual Disability: What We Know and What We Do Not Know.","authors":"Sandra Marquis, Renée O'Leary, N Esmé Marquis, Jennifer Baumbusch","doi":"10.2147/DHPS.S558001","DOIUrl":"10.2147/DHPS.S558001","url":null,"abstract":"<p><p>This study asked the questions: what is known and what is not known about medication burden in adults with an intellectual disability. We used a rapid mapping review methodology to collate, describe and catalog the wide variety of evidence in this area. Ninety-one studies were included. Study characteristics, indicators of medication burden and sub-populations at increased risk were catalogued in a table and tabulated as tree maps. The authors concluded that there is evidence of a high medication burden in this population, and that the burden is highest in older adults with an ID, those living in supervised housing and those with diagnosed comorbidities and multi-morbidities. Areas that need further exploration are the total burden of medications used, including the age at which medications are first prescribed and the duration of medication use; the long-term effects of a high medication burden; and the long-term effects of anticholinergic burden. In addition, there is little information on the effects of demographic factors such as race and income.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":"18 ","pages":"558001"},"PeriodicalIF":3.4,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12992441/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147480118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hypersensitivity Reaction to Hyaluronidase After Peribulbar Anesthesia for Cataract Surgery: Two Case Reports. 白内障手术球周麻醉后透明质酸酶过敏反应2例报告。
IF 3.4 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2026-02-10 eCollection Date: 2026-01-01 DOI: 10.2147/DHPS.S543301
Cheng Cheng, Yanfeng Han, Xiaoxi Liu, Weiwei Yu, Nannan Yang

Background: Hypersensitivity reaction to hyaluronidase, though rare, can occur following regional anesthesia in ophthalmic surgery and may mimic serious conditions such as orbital cellulitis. Prompt recognition is critical to avoid misdiagnosis and unnecessary interventions.

Case presentation: We report two cases of hypersensitivity reaction following hyaluronidase-augmented peribulbar anesthesia for cataract surgery. Case 1: A 90-year-old female with no prior allergy history developed progressive periorbital edema extending to the ipsilateral face and neck within 7 hours after surgery. Infection and hemorrhage were excluded via ultrasound. The reaction resolved promptly with antihistamines and systemic corticosteroids. Case 2: A 69-year-old female developed progressive bilateral periorbital edema extending to the forehead, accompanied by moderate pain within 7 hours postoperatively. While her C-reactive protein (CRP) level was within normal limits on the day of surgery, it rose significantly to 33.92 mg/L on postoperative day 1. Given this clinical and laboratory progression, an empirical and prophylactic therapeutic protocol was initiated, including a short course of systemic antibiotics alongside intensified anti-inflammatory treatment. All bacterial and fungal cultures returned negative, confirming a non-infectious etiology. Both patients achieved complete resolution of symptoms with uneventful recoveries maintained at both the one-week and one-month postoperative follow-up visits.

Conclusion: These cases illustrate that hyaluronidase hypersensitivity, though uncommon, should be considered in the differential diagnosis of acute postoperative periorbital inflammation. A combination of clinical vigilance, targeted imaging, and judicious use of laboratory tests is key to distinguishing this condition from infectious complications. Early diagnosis and a structured management approach are crucial to ensure patient safety and optimal outcomes.

背景:透明质酸酶的超敏反应虽然罕见,但可在眼科手术区域麻醉后发生,并可模拟严重的情况,如眼眶蜂窝织炎。及时识别对于避免误诊和不必要的干预至关重要。病例介绍:我们报告两例白内障手术透明质酸酶增强球周麻醉后的超敏反应。病例1:一名90岁女性,既往无过敏史,术后7小时内出现进行性眶周水肿,延伸至同侧面部和颈部。超声检查排除感染和出血。用抗组胺药和全身皮质类固醇治疗后,反应迅速消失。病例2:69岁女性,术后7小时内出现进行性双侧眶周水肿,延伸至前额,伴中度疼痛。手术当天c反应蛋白(CRP)水平在正常范围内,术后第1天显著升高至33.92 mg/L。鉴于这一临床和实验室进展,启动了一项经验性和预防性治疗方案,包括短期全身性抗生素治疗和强化抗炎治疗。所有细菌和真菌培养结果均为阴性,证实非感染性病因。两例患者在术后1周和1个月的随访中均实现了症状的完全缓解和平稳恢复。结论:这些病例说明透明质酸酶过敏虽然不常见,但在急性术后眶周炎症的鉴别诊断中应予以考虑。结合临床警惕、有针对性的影像学检查和明智地使用实验室检查是将这种疾病与感染性并发症区分开来的关键。早期诊断和结构化的管理方法对于确保患者安全和最佳结果至关重要。
{"title":"Hypersensitivity Reaction to Hyaluronidase After Peribulbar Anesthesia for Cataract Surgery: Two Case Reports.","authors":"Cheng Cheng, Yanfeng Han, Xiaoxi Liu, Weiwei Yu, Nannan Yang","doi":"10.2147/DHPS.S543301","DOIUrl":"https://doi.org/10.2147/DHPS.S543301","url":null,"abstract":"<p><strong>Background: </strong>Hypersensitivity reaction to hyaluronidase, though rare, can occur following regional anesthesia in ophthalmic surgery and may mimic serious conditions such as orbital cellulitis. Prompt recognition is critical to avoid misdiagnosis and unnecessary interventions.</p><p><strong>Case presentation: </strong>We report two cases of hypersensitivity reaction following hyaluronidase-augmented peribulbar anesthesia for cataract surgery. Case 1: A 90-year-old female with no prior allergy history developed progressive periorbital edema extending to the ipsilateral face and neck within 7 hours after surgery. Infection and hemorrhage were excluded via ultrasound. The reaction resolved promptly with antihistamines and systemic corticosteroids. Case 2: A 69-year-old female developed progressive bilateral periorbital edema extending to the forehead, accompanied by moderate pain within 7 hours postoperatively. While her C-reactive protein (CRP) level was within normal limits on the day of surgery, it rose significantly to 33.92 mg/L on postoperative day 1. Given this clinical and laboratory progression, an empirical and prophylactic therapeutic protocol was initiated, including a short course of systemic antibiotics alongside intensified anti-inflammatory treatment. All bacterial and fungal cultures returned negative, confirming a non-infectious etiology. Both patients achieved complete resolution of symptoms with uneventful recoveries maintained at both the one-week and one-month postoperative follow-up visits.</p><p><strong>Conclusion: </strong>These cases illustrate that hyaluronidase hypersensitivity, though uncommon, should be considered in the differential diagnosis of acute postoperative periorbital inflammation. A combination of clinical vigilance, targeted imaging, and judicious use of laboratory tests is key to distinguishing this condition from infectious complications. Early diagnosis and a structured management approach are crucial to ensure patient safety and optimal outcomes.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":"18 ","pages":"543301"},"PeriodicalIF":3.4,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12912024/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146219032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endoscopic Examination and Long-Term Use of Proton Pump Inhibitors for Gastroesophageal Reflux Disease Treatment in Japan. 内镜检查和长期使用质子泵抑制剂治疗胃食管反流病在日本。
IF 3.4 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2026-01-24 eCollection Date: 2026-01-01 DOI: 10.2147/DHPS.S583501
Akina Takami, Gen Terashima, Yuichi Shiotsuki, Koki Yamashita, Ataru Igarashi

Introduction: Long-term use of proton pump inhibitors (PPIs) requires careful observation with endoscopy in Japan. However, there are no studies examining whether monitoring is being properly carried out in clinical practice. Thus, we investigate the usage of PPIs by the presence or absence of endoscopic monitoring using a claims database.

Methods: This study was a retrospective observational cohort study using the nationwide claims database. We obtained data of patients diagnosed with GERD (excluding suspected cases) between April 2014 and March 2024. Inclusion criteria were patients aged 18 years or older, continuously prescribed drugs of interest (omeprazole, lansoprazole, rabeprazole, esomeprazole, and vonoprazan) for 8 weeks or more. To assess the duration of prescriptions over a one-year period, the medication possession ratio (MPR) showing the prescription days per year ratio was examined. MPR was compared between patients who underwent endoscopy [endoscopy(+) group] and those who did not [endoscopy(-) group] during the follow-up period of 12 months.

Results: A total of 398,253 patients [endoscopy(+) group: 142,653; endoscopy(-) group: 255,600] were included in the analysis. The median MPR was 0.534 in the endoscopy(+) group and 0.805 in the endoscopy(-) group; MPR was significantly higher in the endoscopy(-) group (p < 0.0001).

Conclusion: These findings revealed that the long-term administration of PPIs without monitoring esophageal mucosa by endoscopy in patients with GERD is a common practice in Japan. However, compliance with the package inserts suggesting adequate observation, including periodic endoscopic examinations, should be highlighted to ensure safety.

简介:在日本,长期使用质子泵抑制剂(PPIs)需要通过内窥镜仔细观察。然而,没有研究检查在临床实践中是否进行了适当的监测。因此,我们通过使用索赔数据库通过内窥镜监测的存在或缺失来调查ppi的使用情况。方法:本研究是一项回顾性观察队列研究,使用全国索赔数据库。我们获得了2014年4月至2024年3月期间诊断为GERD的患者(不包括疑似病例)的数据。纳入标准为年龄在18岁及以上,连续服用感兴趣的药物(奥美拉唑、兰索拉唑、雷贝拉唑、埃索美拉唑和伏诺哌赞)8周及以上的患者。为了评估处方在一年内的持续时间,检查了显示处方天数/年比率的药物占有比(MPR)。比较内镜(+)组和未内镜(-)组患者在随访12个月期间的MPR。结果:共398,253例患者[内镜+组:142,653例;内镜(-)组:255,600例]纳入分析。内镜(+)组中位MPR为0.534,内镜(-)组中位MPR为0.805;内窥镜(-)组MPR显著增高(p < 0.0001)。结论:这些研究结果表明,在日本,胃食管反流患者长期服用PPIs而不通过内镜监测食管粘膜是一种常见的做法。然而,为了确保安全,应强调遵守包装说明书中建议的充分观察,包括定期内窥镜检查。
{"title":"Endoscopic Examination and Long-Term Use of Proton Pump Inhibitors for Gastroesophageal Reflux Disease Treatment in Japan.","authors":"Akina Takami, Gen Terashima, Yuichi Shiotsuki, Koki Yamashita, Ataru Igarashi","doi":"10.2147/DHPS.S583501","DOIUrl":"https://doi.org/10.2147/DHPS.S583501","url":null,"abstract":"<p><strong>Introduction: </strong>Long-term use of proton pump inhibitors (PPIs) requires careful observation with endoscopy in Japan. However, there are no studies examining whether monitoring is being properly carried out in clinical practice. Thus, we investigate the usage of PPIs by the presence or absence of endoscopic monitoring using a claims database.</p><p><strong>Methods: </strong>This study was a retrospective observational cohort study using the nationwide claims database. We obtained data of patients diagnosed with GERD (excluding suspected cases) between April 2014 and March 2024. Inclusion criteria were patients aged 18 years or older, continuously prescribed drugs of interest (omeprazole, lansoprazole, rabeprazole, esomeprazole, and vonoprazan) for 8 weeks or more. To assess the duration of prescriptions over a one-year period, the medication possession ratio (MPR) showing the prescription days per year ratio was examined. MPR was compared between patients who underwent endoscopy [endoscopy(+) group] and those who did not [endoscopy(-) group] during the follow-up period of 12 months.</p><p><strong>Results: </strong>A total of 398,253 patients [endoscopy(+) group: 142,653; endoscopy(-) group: 255,600] were included in the analysis. The median MPR was 0.534 in the endoscopy(+) group and 0.805 in the endoscopy(-) group; MPR was significantly higher in the endoscopy(-) group (p < 0.0001).</p><p><strong>Conclusion: </strong>These findings revealed that the long-term administration of PPIs without monitoring esophageal mucosa by endoscopy in patients with GERD is a common practice in Japan. However, compliance with the package inserts suggesting adequate observation, including periodic endoscopic examinations, should be highlighted to ensure safety.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":"18 ","pages":"583501"},"PeriodicalIF":3.4,"publicationDate":"2026-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13012140/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147510767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chemotherapy-Induced Toxicities in Pediatric Cancer Patients: A Cross-Sectional Survey Using a Child- and Caregiver-Reported Outcome Tool in Tanzania. 儿童癌症患者化疗诱导的毒性:在坦桑尼亚使用儿童和护理人员报告结果工具的横断面调查。
IF 3.4 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2026-01-22 eCollection Date: 2026-01-01 DOI: 10.2147/DHPS.S548441
Deogratias M Katabalo, Esther Njile, Benson R Kidenya, Anthony Cuthbert Liwa, Kristin Schroeder

Background: Chemotherapy remains the cornerstone of pediatric cancer treatment, yet its cytotoxic nature often results in chemotherapy-induced toxicities, adverse effects arising from damage to healthy, rapidly dividing cells. Data describing these toxicities from the patient and caregiver perspective are scarce in sub-Saharan Africa. This study assessed the types, severity, and determinants of Chemotherapy-Induced Toxicities among pediatric cancer patients in Tanzania.

Methodology: A descriptive cross-sectional study was conducted over six months at Bugando Medical Center. Pediatric patients aged birth to 18 years receiving chemotherapy were enrolled. Toxicities were assessed using a locally validated, Swahili-translated version of the Pediatric Patient-Reported Outcomes Common Terminology Criteria for Adverse Events tool. Children aged ≥ 7 years self-reported their symptoms, while caregivers provided proxy reports for younger children and those who can not express themselves. Associations between chemotherapy-induced toxicities and demographic or treatment variables were analysed using multivariate logistic regression to adjust for potential confounding factors or variables (p < 0.05).

Results: Of 120 participants (55.8% male), all experienced at least one Chemotherapy-Induced Toxicity, with a mean of five per participant. The most common toxicities were alopecia (82.5%), taste changes (74.2%), vomiting (44.2%), and nausea (35%). Most events were mild (grade 1). In multivariable analysis, cancer classification was the only significant predictor of toxicity, with solid tumors showing higher odds of ≥ Grade 2 Chemotherapy-induced toxicities compared with hematologic cancers (AOR = 7.42, p = 0.047). Other factors showed no statistically significant associations.

Conclusion: Chemotherapy-induced toxicities were frequent, with most children experiencing multiple symptoms across organ systems. Cancer classification was the only factor significantly associated with higher-grade toxicities. Integrating child- and caregiver-reported outcome measures into pediatric oncology practice could enhance early identification of toxicities, support timely management, and inform national strategies to improve treatment safety and quality of life for children with cancer in Tanzania.

背景:化疗仍然是儿童癌症治疗的基石,但其细胞毒性往往导致化疗引起的毒性,以及对健康、快速分裂的细胞的损害所产生的不良反应。在撒哈拉以南非洲,从患者和护理人员的角度描述这些毒性的数据很少。本研究评估了坦桑尼亚儿童癌症患者化疗引起的毒性的类型、严重程度和决定因素。方法:在布干多医疗中心进行了为期六个月的描述性横断面研究。出生至18岁接受化疗的儿科患者被纳入研究。使用当地验证的斯瓦希里语翻译版本的儿科患者报告结果不良事件通用术语标准工具评估毒性。≥7岁的儿童自行报告症状,而照顾者为年龄较小的儿童和不能表达自己的儿童提供代理报告。使用多变量逻辑回归分析化疗引起的毒性与人口统计学或治疗变量之间的关系,以校正潜在的混杂因素或变量(p < 0.05)。结果:在120名参与者中(55.8%为男性),所有参与者都经历了至少一次化疗引起的毒性,平均每个参与者5次。最常见的毒性是脱发(82.5%)、味觉改变(74.2%)、呕吐(44.2%)和恶心(35%)。大多数事件为轻度(1级)。在多变量分析中,癌症分类是毒性的唯一显著预测因子,与血液学癌症相比,实体肿瘤显示≥2级化疗诱导毒性的几率更高(AOR = 7.42, p = 0.047)。其他因素无统计学意义。结论:化疗引起的毒性是常见的,大多数儿童出现跨器官系统的多重症状。癌症分类是唯一与高级别毒性显著相关的因素。将儿童和护理人员报告的结果措施纳入儿科肿瘤学实践,可以加强毒性的早期识别,支持及时管理,并为坦桑尼亚提高癌症儿童治疗安全性和生活质量的国家战略提供信息。
{"title":"Chemotherapy-Induced Toxicities in Pediatric Cancer Patients: A Cross-Sectional Survey Using a Child- and Caregiver-Reported Outcome Tool in Tanzania.","authors":"Deogratias M Katabalo, Esther Njile, Benson R Kidenya, Anthony Cuthbert Liwa, Kristin Schroeder","doi":"10.2147/DHPS.S548441","DOIUrl":"https://doi.org/10.2147/DHPS.S548441","url":null,"abstract":"<p><strong>Background: </strong>Chemotherapy remains the cornerstone of pediatric cancer treatment, yet its cytotoxic nature often results in chemotherapy-induced toxicities, adverse effects arising from damage to healthy, rapidly dividing cells. Data describing these toxicities from the patient and caregiver perspective are scarce in sub-Saharan Africa. This study assessed the types, severity, and determinants of Chemotherapy-Induced Toxicities among pediatric cancer patients in Tanzania.</p><p><strong>Methodology: </strong>A descriptive cross-sectional study was conducted over six months at Bugando Medical Center. Pediatric patients aged birth to 18 years receiving chemotherapy were enrolled. Toxicities were assessed using a locally validated, Swahili-translated version of the Pediatric Patient-Reported Outcomes Common Terminology Criteria for Adverse Events tool. Children aged ≥ 7 years self-reported their symptoms, while caregivers provided proxy reports for younger children and those who can not express themselves. Associations between chemotherapy-induced toxicities and demographic or treatment variables were analysed using multivariate logistic regression to adjust for potential confounding factors or variables (p < 0.05).</p><p><strong>Results: </strong>Of 120 participants (55.8% male), all experienced at least one Chemotherapy-Induced Toxicity, with a mean of five per participant. The most common toxicities were alopecia (82.5%), taste changes (74.2%), vomiting (44.2%), and nausea (35%). Most events were mild (grade 1). In multivariable analysis, cancer classification was the only significant predictor of toxicity, with solid tumors showing higher odds of ≥ Grade 2 Chemotherapy-induced toxicities compared with hematologic cancers (AOR = 7.42, p = 0.047). Other factors showed no statistically significant associations.</p><p><strong>Conclusion: </strong>Chemotherapy-induced toxicities were frequent, with most children experiencing multiple symptoms across organ systems. Cancer classification was the only factor significantly associated with higher-grade toxicities. Integrating child- and caregiver-reported outcome measures into pediatric oncology practice could enhance early identification of toxicities, support timely management, and inform national strategies to improve treatment safety and quality of life for children with cancer in Tanzania.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":"18 ","pages":"548441"},"PeriodicalIF":3.4,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13005216/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147497903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of Missed Medication Doses and Outcomes of Hospitalized Patients Living with HIV in Uganda. 乌干达艾滋病毒住院患者的漏药率和结果
IF 3.4 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2026-01-21 eCollection Date: 2026-01-01 DOI: 10.2147/DHPS.S572681
Mary Madalen Angut, Humphrey Atwijukiire, Brian Mushabe, Katusabe Shamim, Brenda Namanda, Charles Mondo, Emmanuel Seremba, Charles Kabugo, Joseph Baruch Baluku

Background: Missed Medication Doses (MMD) are a common but preventable form of medication error that compromise treatment outcomes. Evidence on the burden and consequences of MMD among hospitalized people living with HIV (PLHIV) in Uganda remains limited.

Methods: We conducted a cross-sectional study at KNRH, Kampala, Uganda, reviewing medical records of PLHIV admitted to the infectious diseases unit between January 2022 and December 2023. Eligible files included treatment charts documenting prescribed and administered parenteral medications. Descriptive statistics summarized patient characteristics and prevalence of MMD. Associations between patient factors and MMD were assessed using chi-square tests and multivariable logistic regression. Outcomes examined included length of hospital stay, in-hospital mortality, and readmission.

Results: Of 814 records screened, 462 met the inclusion criteria. Patients were predominantly female (61.0%), with a mean age of 25.8 years (SD 14.4). Overall, 403 patients (87.2%; 95% CI: 84.1-90.0) experienced at least one MMD. Missed doses were common across nearly all medications, with omission rates exceeding 80% for ceftriaxone, paracetamol, metronidazole, omeprazole, metoclopramide, and levofloxacin, and approaching 100% for furosemide, co-amoxiclav, ondansetron, enoxaparin, albumin, and artesunate. Lower odds of MMD were independently associated with Luo ethnicity (aOR = 0.15, 95% CI: 0.03-0.59), separated marital status (aOR = 0.16, 95% CI: 0.03-0.73), and Muslim faith (aOR = 0.21, 95% CI: 0.07-0.61). Older age was associated with a modest increase in risk (aOR = 1.02 per year, p = 0.032). Length of hospital stay did not differ significantly between patients with and without MMD. Overall in-hospital mortality was high (69.0%) and was lower among patients with documented MMD compared to those without (p < 0.001).

Conclusion: Missed parenteral medication doses are highly prevalent among hospitalized PLHIV in Uganda. Strengthening medication administration and documentation systems is urgently needed to improve patient safety and outcomes.

背景:遗漏用药剂量(MMD)是一种常见但可预防的药物错误,影响治疗结果。关于乌干达住院的艾滋病毒感染者中烟雾病的负担和后果的证据仍然有限。方法:我们在乌干达坎帕拉KNRH进行了一项横断面研究,回顾了2022年1月至2023年12月传染病科收治的PLHIV病例。符合条件的文件包括记录处方和注射药物的治疗图表。描述性统计总结了烟雾病的患者特征和患病率。采用卡方检验和多变量logistic回归评估患者因素与烟雾病之间的关系。研究结果包括住院时间、住院死亡率和再入院率。结果:筛选的814条记录中,462条符合纳入标准。患者以女性为主(61.0%),平均年龄25.8岁(SD 14.4)。总体而言,403名患者(87.2%;95% CI: 84.1-90.0)至少经历了一次烟雾病。几乎所有药物的漏给剂量都很常见,头孢曲松、扑热息痛、甲硝唑、奥美拉唑、甲氧氯普胺和左氧氟沙星的漏给率超过80%,呋塞米、共阿莫昔拉、昂丹西琼、依诺肝素、白蛋白和青蒿琥酯的漏给率接近100%。与罗族(aOR = 0.15, 95% CI: 0.03-0.59)、分居婚姻状况(aOR = 0.16, 95% CI: 0.03-0.73)和穆斯林信仰(aOR = 0.21, 95% CI: 0.07-0.61)独立相关。年龄越大,风险适度增加(aOR = 1.02 /年,p = 0.032)。住院时间在烟雾病患者和非烟雾病患者之间没有显著差异。总体住院死亡率高(69.0%),有烟雾病患者的住院死亡率低于无烟雾病患者(p < 0.001)。结论:在乌干达住院的hiv患者中,漏给肠外药物的情况非常普遍。迫切需要加强药物管理和文件系统,以改善患者安全和结果。
{"title":"Prevalence of Missed Medication Doses and Outcomes of Hospitalized Patients Living with HIV in Uganda.","authors":"Mary Madalen Angut, Humphrey Atwijukiire, Brian Mushabe, Katusabe Shamim, Brenda Namanda, Charles Mondo, Emmanuel Seremba, Charles Kabugo, Joseph Baruch Baluku","doi":"10.2147/DHPS.S572681","DOIUrl":"https://doi.org/10.2147/DHPS.S572681","url":null,"abstract":"<p><strong>Background: </strong>Missed Medication Doses (MMD) are a common but preventable form of medication error that compromise treatment outcomes. Evidence on the burden and consequences of MMD among hospitalized people living with HIV (PLHIV) in Uganda remains limited.</p><p><strong>Methods: </strong>We conducted a cross-sectional study at KNRH, Kampala, Uganda, reviewing medical records of PLHIV admitted to the infectious diseases unit between January 2022 and December 2023. Eligible files included treatment charts documenting prescribed and administered parenteral medications. Descriptive statistics summarized patient characteristics and prevalence of MMD. Associations between patient factors and MMD were assessed using chi-square tests and multivariable logistic regression. Outcomes examined included length of hospital stay, in-hospital mortality, and readmission.</p><p><strong>Results: </strong>Of 814 records screened, 462 met the inclusion criteria. Patients were predominantly female (61.0%), with a mean age of 25.8 years (SD 14.4). Overall, 403 patients (87.2%; 95% CI: 84.1-90.0) experienced at least one MMD. Missed doses were common across nearly all medications, with omission rates exceeding 80% for ceftriaxone, paracetamol, metronidazole, omeprazole, metoclopramide, and levofloxacin, and approaching 100% for furosemide, co-amoxiclav, ondansetron, enoxaparin, albumin, and artesunate. Lower odds of MMD were independently associated with Luo ethnicity (aOR = 0.15, 95% CI: 0.03-0.59), separated marital status (aOR = 0.16, 95% CI: 0.03-0.73), and Muslim faith (aOR = 0.21, 95% CI: 0.07-0.61). Older age was associated with a modest increase in risk (aOR = 1.02 per year, p = 0.032). Length of hospital stay did not differ significantly between patients with and without MMD. Overall in-hospital mortality was high (69.0%) and was lower among patients with documented MMD compared to those without (p < 0.001).</p><p><strong>Conclusion: </strong>Missed parenteral medication doses are highly prevalent among hospitalized PLHIV in Uganda. Strengthening medication administration and documentation systems is urgently needed to improve patient safety and outcomes.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":"18 ","pages":"572681"},"PeriodicalIF":3.4,"publicationDate":"2026-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13007539/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147509208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adverse Events Associated with Tirzepatide: Updated Pharmacovigilance Analysis Using FAERS (2022 Q1-2025 Q1) with an Adapted Time-to-Onset Method. 与替西肽相关的不良事件:使用FAERS(2022年第一季度-2025年第一季度)更新的药物警戒分析,采用适应的发病时间方法。
IF 3.4 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2026-01-08 eCollection Date: 2026-01-01 DOI: 10.2147/DHPS.S556918
Saisai Gu

Purpose: Tirzepatide, the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist with rapidly expanding clinical use, requires detailed post-marketing pharmacovigilance to monitor emerging safety signals. This study aims to identify and characterize specific adverse events (AEs) associated with tirzepatide utilizing FDA Adverse Event Reporting System (FAERS).

Patients and methods: The datasets were cleaned and standardized using Python, a programming language for data processing, and MySQL, a database management system, to ensure accuracy and consistency before analysis. Subsequently, AE signals were detected via four quantitative disproportionality algorithms, sorted and categorized by demographics, gender, and clinical prioritization, with a modified Weibull model developed to analyze AE onset timing.

Results: A total of 67,305 cases (75.83% female) and 137,583 adverse events were identified related to tirzepatide. One hundred and forty-four AE signals showed statistically significant signals suggesting a potential association with tirzepatide, with several new including postmenopausal haemorrhage and menstrual disorder (implying regulatory interference on sex hormones), Wernicke's encephalopathy and sleep disorder (malnutrition caused by low intake). Pancreatitis, impaired gastric emptying, dehydration and cholelithiasis carried higher risks with serious clinical outcomes. Sleep disorder, delayed gastric emptying, and medullary thyroid cancer are more common in males; starvation ketoacidosis and incorrect injection site, in females. The median time-to-onset (TTO) was 6.36 days (Interquartile Range (IQR) 0.85-31.2) with the Weibull shape parameter (β) of 0.44, indicating an early failure profile.

Conclusion: This study uncovered new risks of tirzepatide, including AEs associated with skin, menstruation, psychiatric and nervous system. Median TTO was corrected to within a week, highlighting the need for early monitoring before clinicians prescribe tirzepatide, and special attention should be given to patients who have pre-existing digestive dysfunction, malnutrition, or a family history of thyroid disease.

目的:tizepatide是第一种临床应用迅速扩大的双葡萄糖依赖性胰岛素性多肽(GIP)和胰高血糖素样肽-1 (GLP-1)受体激动剂,需要详细的上市后药物警戒来监测新出现的安全性信号。本研究旨在利用FDA不良事件报告系统(FAERS)识别和描述与替西肽相关的特定不良事件(ae)。患者和方法:在分析前,使用数据处理编程语言Python和数据库管理系统MySQL对数据集进行清理和标准化,以确保数据集的准确性和一致性。随后,通过四种定量歧化算法检测声发射信号,根据人口统计学、性别和临床优先级进行排序和分类,并开发了一种改进的Weibull模型来分析声发射的发病时间。结果:共发现与替西肽相关的不良事件67,305例(女性75.83%),137,583例。144个AE信号显示具有统计学意义的信号,表明与替西肽有潜在的关联,其中包括绝经后出血和月经紊乱(暗示性激素的调节干扰),韦尼克脑病和睡眠障碍(低摄入量引起的营养不良)。胰腺炎、胃排空功能受损、脱水和胆石症的风险较高,具有严重的临床后果。睡眠障碍、胃排空延迟和甲状腺髓样癌在男性中更为常见;饥饿酮症酸中毒和注射部位不正确的女性。中位发病时间(TTO)为6.36天(四分位间距(IQR) 0.85-31.2),威布尔形状参数(β)为0.44,提示早期失效。结论:本研究揭示了替西帕肽的新风险,包括与皮肤、月经、精神和神经系统相关的ae。中位TTO被修正为在一周内,强调在临床医生开替西帕肽之前需要进行早期监测,并应特别注意已有消化功能障碍、营养不良或甲状腺疾病家族史的患者。
{"title":"Adverse Events Associated with Tirzepatide: Updated Pharmacovigilance Analysis Using FAERS (2022 Q1-2025 Q1) with an Adapted Time-to-Onset Method.","authors":"Saisai Gu","doi":"10.2147/DHPS.S556918","DOIUrl":"10.2147/DHPS.S556918","url":null,"abstract":"<p><strong>Purpose: </strong>Tirzepatide, the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist with rapidly expanding clinical use, requires detailed post-marketing pharmacovigilance to monitor emerging safety signals. This study aims to identify and characterize specific adverse events (AEs) associated with tirzepatide utilizing FDA Adverse Event Reporting System (FAERS).</p><p><strong>Patients and methods: </strong>The datasets were cleaned and standardized using Python, a programming language for data processing, and MySQL, a database management system, to ensure accuracy and consistency before analysis. Subsequently, AE signals were detected via four quantitative disproportionality algorithms, sorted and categorized by demographics, gender, and clinical prioritization, with a modified Weibull model developed to analyze AE onset timing.</p><p><strong>Results: </strong>A total of 67,305 cases (75.83% female) and 137,583 adverse events were identified related to tirzepatide. One hundred and forty-four AE signals showed statistically significant signals suggesting a potential association with tirzepatide, with several new including postmenopausal haemorrhage and menstrual disorder (implying regulatory interference on sex hormones), Wernicke's encephalopathy and sleep disorder (malnutrition caused by low intake). Pancreatitis, impaired gastric emptying, dehydration and cholelithiasis carried higher risks with serious clinical outcomes. Sleep disorder, delayed gastric emptying, and medullary thyroid cancer are more common in males; starvation ketoacidosis and incorrect injection site, in females. The median time-to-onset (TTO) was 6.36 days (Interquartile Range (IQR) 0.85-31.2) with the Weibull shape parameter (β) of 0.44, indicating an early failure profile.</p><p><strong>Conclusion: </strong>This study uncovered new risks of tirzepatide, including AEs associated with skin, menstruation, psychiatric and nervous system. Median TTO was corrected to within a week, highlighting the need for early monitoring before clinicians prescribe tirzepatide, and special attention should be given to patients who have pre-existing digestive dysfunction, malnutrition, or a family history of thyroid disease.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":"18 ","pages":"556918"},"PeriodicalIF":3.4,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12794925/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145965570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Digoxin Toxicity at Standard Doses in a Child with Subclinical Elevation of Thyrotrophin: A Case Report. 标准剂量地高辛对亚临床促甲状腺素升高儿童的毒性:1例报告。
IF 3.4 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2025-12-23 eCollection Date: 2025-01-01 DOI: 10.2147/DHPS.S553017
Mohammadrafie Khorgami, Mohammad Dalili, Bahareh Karimian

Digoxin toxicity poses a challenge for patients using the drug. Electrolyte disturbances, renal failure, and drug interactions are common predisposing factors. Hypothyroidism can increase the risk of digoxin toxicity primarily. This research reports a 7-year-old boy receiving digoxin 6 μg/kg/day presented with nausea and second-degree atrioventricular block secondary to ongoing digoxin toxicity. Initiation of levothyroxine for subclinical elevation of thyrotrophin resulted in rapid resolution of symptoms and normalization of digoxin levels.

地高辛的毒性对使用该药物的患者构成了挑战。电解质紊乱、肾功能衰竭和药物相互作用是常见的诱发因素。甲状腺功能减退可增加地高辛中毒的风险。本研究报告一名7岁男孩接受6 μg/kg/天地高辛治疗后出现恶心和二级房室传导阻滞,继发于持续的地高辛毒性。亚临床促甲状腺素升高开始左旋甲状腺素导致症状迅速消退和地高辛水平正常化。
{"title":"Digoxin Toxicity at Standard Doses in a Child with Subclinical Elevation of Thyrotrophin: A Case Report.","authors":"Mohammadrafie Khorgami, Mohammad Dalili, Bahareh Karimian","doi":"10.2147/DHPS.S553017","DOIUrl":"10.2147/DHPS.S553017","url":null,"abstract":"<p><p>Digoxin toxicity poses a challenge for patients using the drug. Electrolyte disturbances, renal failure, and drug interactions are common predisposing factors. Hypothyroidism can increase the risk of digoxin toxicity primarily. This research reports a 7-year-old boy receiving digoxin 6 μg/kg/day presented with nausea and second-degree atrioventricular block secondary to ongoing digoxin toxicity. Initiation of levothyroxine for subclinical elevation of thyrotrophin resulted in rapid resolution of symptoms and normalization of digoxin levels.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":"17 ","pages":"265-267"},"PeriodicalIF":3.4,"publicationDate":"2025-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12743475/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145849069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of Knowledge, Attitudes, and Practices on Antibiotic Use and Resistance Among Healthcare Workers in Monrovia, Liberia: A Facility-Based Cross-Sectional Study. 利比里亚蒙罗维亚医护人员抗生素使用和耐药性的知识、态度和实践评估:一项基于设施的横断面研究。
IF 3.4 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2025-11-19 eCollection Date: 2025-01-01 DOI: 10.2147/DHPS.S564658
Bode Ireti Shobayo, Victor Saah Taylor, Bluefin Masell Freeman, James Saysay Kokro, Sampson K P Chea

Background: Globally, healthcare systems are currently facing a significant challenge in terms of antibiotic resistance. Healthcare professionals actively participate in the process of prescribing, dispensing and administering antibiotics.

Objective: We examined the knowledge, attitudes and practices regarding antibiotic use and antibiotic resistance among healthcare professionals working in a tertiary hospital located in Monrovia, Liberia.

Methods: A hospital-based cross-sectional survey was carried out from January to June, 2023 involving 61 healthcare workers at the ELWA Hospital, Liberia. A purposive sample of healthcare workers across diverse professional roles was surveyed using a structured questionnaire on antibiotic use and resistance. Data were analyzed in SPSS v25 using descriptive statistics to summarize participant characteristics and inferential tests to explore variable associations.

Results: Participants ages ranged from 20 to 60 years (mean = 40.7 ± 5) and nurses constituted the majority professional group (59%). Most respondents (68.9%) disagreed that antibiotics are effective against viral infections (OR = 0.45; p = 0.020). However, 36.1% believed antibiotics could be stopped when symptoms resolve and 24.6% believed leftover antibiotics could be reused (OR = 0.33; p = 0.002). Majority, 72.1% and 70.5%, reported never using antibiotics for body pain or headaches, respectively (OR = 3.67; p = 0.001 and OR = 4.78; p < 0.001). Despite this, 39.3% admitted to sometimes or always storing leftover antibiotics and 39.3% agreed or strongly agreed that stopping antibiotics early is safe (OR = 0.36; p = 0.016).

Conclusion: The study identified persistent gaps in healthcare workers' knowledge, attitudes, and practices regarding antibiotic use and resistance, despite encouraging awareness in some areas. Misconceptions such as premature discontinuation and reuse of leftover antibiotics were common. Findings underscore the need for targeted education and strengthened stewardship programs in Liberia's healthcare settings.

背景:在全球范围内,卫生保健系统目前正面临着抗生素耐药性方面的重大挑战。医护专业人员积极参与处方、配发和施用抗生素的过程。目的:我们调查了利比里亚蒙罗维亚一家三级医院医护人员关于抗生素使用和抗生素耐药性的知识、态度和做法。方法:于2023年1月至6月对利比里亚ELWA医院61名医护人员进行了以医院为基础的横断面调查。使用结构化的抗生素使用和耐药性问卷对不同专业角色的卫生保健工作者进行了有目的的抽样调查。在SPSS v25中对数据进行分析,采用描述性统计总结参与者特征,并采用推理检验探讨变量间的关联。结果:参与者年龄在20 ~ 60岁之间(平均= 40.7±5),以护士为主(59%)。大多数应答者(68.9%)不认为抗生素对病毒感染有效(OR = 0.45; p = 0.020)。然而,36.1%的人认为症状缓解后可以停用抗生素,24.6%的人认为剩余抗生素可以重复使用(OR = 0.33; p = 0.002)。大多数(72.1%和70.5%)报告从未因身体疼痛或头痛使用抗生素(or = 3.67; p = 0.001和or = 4.78; p < 0.001)。尽管如此,39.3%的人承认有时或总是储存剩余的抗生素,39.3%的人同意或强烈同意早期停用抗生素是安全的(or = 0.36; p = 0.016)。结论:该研究确定了卫生保健工作者关于抗生素使用和耐药性的知识、态度和实践方面的持续差距,尽管在某些领域鼓励了认识。过早停用和重复使用剩余抗生素等误解很常见。调查结果强调了在利比里亚的医疗环境中需要有针对性的教育和加强管理方案。
{"title":"Assessment of Knowledge, Attitudes, and Practices on Antibiotic Use and Resistance Among Healthcare Workers in Monrovia, Liberia: A Facility-Based Cross-Sectional Study.","authors":"Bode Ireti Shobayo, Victor Saah Taylor, Bluefin Masell Freeman, James Saysay Kokro, Sampson K P Chea","doi":"10.2147/DHPS.S564658","DOIUrl":"10.2147/DHPS.S564658","url":null,"abstract":"<p><strong>Background: </strong>Globally, healthcare systems are currently facing a significant challenge in terms of antibiotic resistance. Healthcare professionals actively participate in the process of prescribing, dispensing and administering antibiotics.</p><p><strong>Objective: </strong>We examined the knowledge, attitudes and practices regarding antibiotic use and antibiotic resistance among healthcare professionals working in a tertiary hospital located in Monrovia, Liberia.</p><p><strong>Methods: </strong>A hospital-based cross-sectional survey was carried out from January to June, 2023 involving 61 healthcare workers at the ELWA Hospital, Liberia. A purposive sample of healthcare workers across diverse professional roles was surveyed using a structured questionnaire on antibiotic use and resistance. Data were analyzed in SPSS v25 using descriptive statistics to summarize participant characteristics and inferential tests to explore variable associations.</p><p><strong>Results: </strong>Participants ages ranged from 20 to 60 years (mean = 40.7 ± 5) and nurses constituted the majority professional group (59%). Most respondents (68.9%) disagreed that antibiotics are effective against viral infections (OR = 0.45; p = 0.020). However, 36.1% believed antibiotics could be stopped when symptoms resolve and 24.6% believed leftover antibiotics could be reused (OR = 0.33; p = 0.002). Majority, 72.1% and 70.5%, reported never using antibiotics for body pain or headaches, respectively (OR = 3.67; p = 0.001 and OR = 4.78; p < 0.001). Despite this, 39.3% admitted to sometimes or always storing leftover antibiotics and 39.3% agreed or strongly agreed that stopping antibiotics early is safe (OR = 0.36; p = 0.016).</p><p><strong>Conclusion: </strong>The study identified persistent gaps in healthcare workers' knowledge, attitudes, and practices regarding antibiotic use and resistance, despite encouraging awareness in some areas. Misconceptions such as premature discontinuation and reuse of leftover antibiotics were common. Findings underscore the need for targeted education and strengthened stewardship programs in Liberia's healthcare settings.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":"17 ","pages":"253-264"},"PeriodicalIF":3.4,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12640598/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145596147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current Status and Research Trends in Deprescribing: A Bibliometric Review. 文献计量学综述:处方描述的现状与研究趋势。
IF 3.4 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2025-11-18 eCollection Date: 2025-01-01 DOI: 10.2147/DHPS.S557043
Changcheng Shi, Xinyi Li, Yan Wu, Wangjun Qin, Lihong Liu

Background: Polypharmacy has emerged as a major global public health concern. To mitigate its adverse effects, deprescribing has been introduced and integrated into clinical practice. This study aims to analyze the current research landscape and identify emerging trends in deprescribing from a bibliometric perspective.

Methods: Relevant studies on deprescribing published prior to December 2024 were retrieved from the Web of Science Core Collection database. Bibliometric analysis and visualization of co-authorship, citation, co-citation, co-occurrence, and burst detection were performed using VOSviewer, CiteSpace, and Bibliometrix.

Results: A total of 1809 publications were identified, with a marked increase over the past decade. The field is dominated by contributions from developed countries, notably the United States, Australia, and Canada. Studies primarily focus on chronic conditions, such as psychiatric disorders, cardiometabolic diseases, and chronic pain, and the medications used to treat them. Influential publications highlighted barriers and facilitators of deprescribing, deprescribing tools, and deprescribing interventions and their associated outcomes. Burst detection analysis pointed to increasing attention on pharmaceutical care and implementation science.

Conclusion: This study presents the first comprehensive bibliometric overview of deprescribing. The findings demonstrate that the field has grown rapidly but remains dominated by developed countries and a limited set of chronic diseases. The integration of implementation science frameworks emerges as a promising approach to enhance the design and evaluation of deprescribing interventions. Future studies should broaden their scope to include a wider range of diseases and medications, and encourage greater participation from developing countries.

背景:综合用药已成为一个主要的全球公共卫生问题。为了减轻其不良影响,处方化已被引入并纳入临床实践。本研究旨在从文献计量学的角度分析当前的研究现状,并确定描述的新趋势。方法:检索Web of Science Core Collection数据库中2024年12月前发表的有关处方描述的相关研究。使用VOSviewer、CiteSpace和Bibliometrix对合著、被引、共被引、共现和突发检测进行文献计量学分析和可视化。结果:共确定了1809篇出版物,在过去十年中显著增加。该领域的贡献主要来自发达国家,特别是美国、澳大利亚和加拿大。研究主要集中于慢性疾病,如精神疾病、心脏代谢疾病和慢性疼痛,以及用于治疗这些疾病的药物。有影响力的出版物强调了开处方、开处方工具和开处方干预措施及其相关结果的障碍和促进因素。突发检测分析表明,越来越重视药学服务和实施科学。结论:本研究提出了第一个全面的文献计量学概述的处方。研究结果表明,该领域发展迅速,但仍由发达国家和有限的慢性疾病所主导。整合实施科学框架是加强处方性干预措施的设计和评估的一种有希望的方法。今后的研究应扩大其范围,包括更广泛的疾病和药物,并鼓励发展中国家更多地参与。
{"title":"Current Status and Research Trends in Deprescribing: A Bibliometric Review.","authors":"Changcheng Shi, Xinyi Li, Yan Wu, Wangjun Qin, Lihong Liu","doi":"10.2147/DHPS.S557043","DOIUrl":"10.2147/DHPS.S557043","url":null,"abstract":"<p><strong>Background: </strong>Polypharmacy has emerged as a major global public health concern. To mitigate its adverse effects, deprescribing has been introduced and integrated into clinical practice. This study aims to analyze the current research landscape and identify emerging trends in deprescribing from a bibliometric perspective.</p><p><strong>Methods: </strong>Relevant studies on deprescribing published prior to December 2024 were retrieved from the Web of Science Core Collection database. Bibliometric analysis and visualization of co-authorship, citation, co-citation, co-occurrence, and burst detection were performed using VOSviewer, CiteSpace, and Bibliometrix.</p><p><strong>Results: </strong>A total of 1809 publications were identified, with a marked increase over the past decade. The field is dominated by contributions from developed countries, notably the United States, Australia, and Canada. Studies primarily focus on chronic conditions, such as psychiatric disorders, cardiometabolic diseases, and chronic pain, and the medications used to treat them. Influential publications highlighted barriers and facilitators of deprescribing, deprescribing tools, and deprescribing interventions and their associated outcomes. Burst detection analysis pointed to increasing attention on pharmaceutical care and implementation science.</p><p><strong>Conclusion: </strong>This study presents the first comprehensive bibliometric overview of deprescribing. The findings demonstrate that the field has grown rapidly but remains dominated by developed countries and a limited set of chronic diseases. The integration of implementation science frameworks emerges as a promising approach to enhance the design and evaluation of deprescribing interventions. Future studies should broaden their scope to include a wider range of diseases and medications, and encourage greater participation from developing countries.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":"17 ","pages":"239-252"},"PeriodicalIF":3.4,"publicationDate":"2025-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12640142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145586325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Drug, Healthcare and Patient Safety
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1